,Term,Overlap,P.value,Adjusted.P.value,-LOG10(pvalue),Old.P.value,Old.Adjusted.P.value,Odds.Ratio,Combined.Score,Genes
1,GnRH secretion,5/64,1.40E-05,0.002320501,4.854526333,0,0,18.48109518,206.580942,CACNA1I;NRAS;ITPR3;CACNA1H;KCNJ3
2,Circadian entrainment,5/97,0.000104302,0.008657096,3.98170588,0,0,11.83229814,108.4810722,GRIA2;CACNA1I;ITPR3;CACNA1H;KCNJ3
3,Apelin signaling pathway,5/137,0.000519987,0.028520768,3.284007603,0,0,8.23010323,62.23362881,EGR1;MEF2C;NRAS;CCND1;ITPR3
4,Oxytocin signaling pathway,5/154,0.00088268,0.028520768,3.054196952,0,0,7.284829265,51.23091418,MEF2C;NRAS;CCND1;ITPR3;KCNJ3
5,Bladder cancer,3/41,0.001000898,0.028520768,2.999610046,0,0,16.86417657,116.4784623,NRAS;CCND1;MMP2
6,GnRH signaling pathway,4/93,0.001049908,0.028520768,2.978848921,0,0,9.680019541,66.39576822,EGR1;NRAS;MMP2;ITPR3
7,Aldosterone synthesis and secretion,4/98,0.001275467,0.028520768,2.894330736,0,0,9.162812211,61.06503794,CACNA1I;ITPR3;ATP2B1;CACNA1H
8,AGE-RAGE signaling pathway in diabetic complications,4/100,0.001374495,0.028520768,2.861856885,0,0,8.971014493,59.11601611,EGR1;NRAS;CCND1;MMP2
9,C-type lectin receptor signaling pathway,4/104,0.001588443,0.029297949,2.799028359,0,0,8.610434783,55.49426056,NRAS;EGR2;EGR3;ITPR3
10,Axon guidance,5/182,0.001850682,0.030721325,2.73266815,0,0,6.123735022,38.53177129,EPHA7;NRAS;SEMA3D;SEMA3A;SEMA4F
11,Cholinergic synapse,4/113,0.002152582,0.032484426,2.667040207,0,0,7.895891504,48.48935685,NRAS;KCNQ2;ITPR3;KCNJ3
12,MAPK signaling pathway,6/294,0.002941669,0.038416507,2.531406161,0,0,4.540740741,26.46697015,CACNA1I;MEF2C;NRAS;MECOM;DUSP6;CACNA1H
13,Long-term depression,3/60,0.003008522,0.038416507,2.521646859,0,0,11.23203169,65.21661826,GRIA2;NRAS;ITPR3
14,Dopaminergic synapse,4/132,0.003769953,0.03968367,2.423664022,0,0,6.717391304,37.48769626,GRIA2;ITPR3;CLOCK;KCNJ3
15,Cortisol synthesis and secretion,3/65,0.003774492,0.03968367,2.423141445,0,0,10.32362123,57.60053491,CACNA1I;ITPR3;CACNA1H
16,Acute myeloid leukemia,3/67,0.004111119,0.03968367,2.38603993,0,0,10,54.94059974,NRAS;CCND1;DUSP6
17,Long-term potentiation,3/67,0.004111119,0.03968367,2.38603993,0,0,10,54.94059974,GRIA2;NRAS;ITPR3
18,Estrogen signaling pathway,4/137,0.004303049,0.03968367,2.366223756,0,0,6.463223276,35.21442959,NRAS;MMP2;ITPR3;KCNJ3
19,Chronic myeloid leukemia,3/76,0.005848776,0.05109983,2.232935031,0,0,8.763146266,45.05591735,NRAS;MECOM;CCND1
20,Cushing syndrome,4/155,0.006639629,0.05510892,2.177856195,0,0,5.68758998,28.52155297,CACNA1I;CCND1;ITPR3;CACNA1H
21,Thyroid cancer,2/37,0.013614786,0.107621645,1.865989168,0,0,12.07841945,51.89612303,NRAS;CCND1
22,"Parathyroid hormone synthesis, secretion and action",3/106,0.014480229,0.109259909,1.839224573,0,0,6.201378014,26.26265657,EGR1;MEF2C;ITPR3
23,Viral carcinogenesis,4/203,0.016582669,0.112126806,1.780345578,0,0,4.305221761,17.64881399,NRAS;EGR2;EGR3;CCND1
24,Proteoglycans in cancer,4/205,0.0171274,0.112126806,1.766308567,0,0,4.261951114,17.33367814,NRAS;CCND1;MMP2;ITPR3
25,Serotonergic synapse,3/113,0.017158364,0.112126806,1.765524126,0,0,5.804692082,23.59763787,NRAS;ITPR3;KCNJ3
26,Glutamatergic synapse,3/114,0.01756203,0.112126806,1.755425288,0,0,5.752106946,23.25010888,GRIA2;ITPR3;KCNJ3
27,Human T-cell leukemia virus 1 infection,4/219,0.021254623,0.130676573,1.672546586,0,0,3.981597573,15.33385228,EGR1;NRAS;EGR2;CCND1
28,FoxO signaling pathway,3/131,0.025235806,0.149612277,1.597982823,0,0,4.983870968,18.3381105,NRAS;CCND1;PLK2
29,Calcium signaling pathway,4/240,0.028505559,0.163169751,1.545070439,0,0,3.623434046,12.89093245,CACNA1I;ITPR3;ATP2B1;CACNA1H
30,Spinocerebellar ataxia,3/143,0.031575814,0.16959006,1.500645449,0,0,4.553917051,15.73544031,GRIA2;RELN;ITPR3
31,Endometrial cancer,2/58,0.031670433,0.16959006,1.499346002,0,0,7.541033435,26.03445082,NRAS;CCND1
32,Retrograde endocannabinoid signaling,3/148,0.034441474,0.178665144,1.462918275,0,0,4.395773081,14.80713442,GRIA2;ITPR3;KCNJ3
33,Lysine degradation,2/63,0.03684788,0.185356001,1.433587497,0,0,6.921171957,22.84649241,MECOM;KMT2C
34,Cellular senescence,3/156,0.039297665,0.191865071,1.405633252,0,0,4.164242041,13.47794486,NRAS;CCND1;ITPR3
35,Hepatitis B,3/162,0.043156387,0.194993869,1.364954917,0,0,4.005883546,12.59019092,NRAS;EGR2;EGR3
36,Prolactin signaling pathway,2/70,0.044597402,0.194993869,1.350690438,0,0,6.206508135,19.30273476,NRAS;CCND1
37,cGMP-PKG signaling pathway,3/167,0.04651193,0.194993869,1.332435635,0,0,3.882769473,11.91251702,MEF2C;ITPR3;ATP2B1
38,Melanoma,2/72,0.046913263,0.194993869,1.328704356,0,0,6.028571429,18.44414206,NRAS;CCND1
39,Non-small cell lung cancer,2/72,0.046913263,0.194993869,1.328704356,0,0,6.028571429,18.44414206,NRAS;CCND1
40,Synthesis and degradation of ketone bodies,10-Jan,0.046986474,0.194993869,1.32802714,0,0,23.26900585,71.15418818,HMGCS1
41,Glioma,2/75,0.050467894,0.204333425,1.296984816,0,0,5.779947537,17.2613388,NRAS;CCND1
42,MicroRNAs in cancer,4/310,0.062226298,0.241473858,1.206026037,0,0,2.784597897,7.732765915,NRAS;MARCKS;CCND1;SPRY2
43,Colorectal cancer,2/86,0.064280083,0.241473858,1.191923571,0,0,5.020263425,13.77814031,NRAS;CCND1
44,Transcriptional misregulation in cancer,3/192,0.065138031,0.241473858,1.186165376,0,0,3.364908687,9.190395788,MEF2C;ETV1;DUSP6
45,Kaposi sarcoma-associated herpesvirus infection,3/193,0.065945109,0.241473858,1.180817411,0,0,3.347028862,9.100345779,NRAS;CCND1;ITPR3
46,Gap junction,2/88,0.066914443,0.241473858,1.174480136,0,0,4.903018308,13.25943075,NRAS;ITPR3
47,Salivary secretion,2/93,0.07365378,0.260138883,1.13280496,0,0,4.632452654,12.08319599,ITPR3;ATP2B1
48,Nitrogen metabolism,17-Jan,0.078570462,0.268295688,1.104740694,0,0,13.08421053,33.28308422,CPS1
49,Prostate cancer,2/97,0.079195715,0.268295688,1.101298315,0,0,4.436506159,11.25023909,NRAS;CCND1
50,Pancreatic secretion,2/102,0.086299864,0.28651555,1.063989886,0,0,4.213617021,10.32305517,ITPR3;ATP2B1
51,Steroid biosynthesis,20-Jan,0.091787274,0.298758578,1.037217528,0,0,11.0166205,26.31079223,CYP2R1
52,Human cytomegalovirus infection,3/225,0.09410964,0.300426928,1.026365888,0,0,2.859924441,6.758844541,NRAS;CCND1;ITPR3
53,Arginine biosynthesis,22-Jan,0.100494079,0.308926243,0.997859525,0,0,9.96641604,22.89940028,CPS1
54,Terpenoid backbone biosynthesis,22-Jan,0.100494079,0.308926243,0.997859525,0,0,9.96641604,22.89940028,HMGCS1
55,Renin-angiotensin system,23-Jan,0.104816455,0.316355118,0.979570533,0,0,9.51291866,21.45681143,AGTR2
56,"Growth hormone synthesis, secretion and action",2/119,0.111757737,0.331281865,0.951722399,0,0,3.598290598,7.885372492,NRAS;ITPR3
57,Thyroid hormone signaling pathway,2/121,0.114870592,0.334535409,0.93979114,0,0,3.537457536,7.654877944,NRAS;CCND1
58,Biosynthesis of unsaturated fatty acids,27-Jan,0.121901375,0.342976751,0.913991394,0,0,8.047773279,16.9368846,ELOVL6
59,Fatty acid elongation,27-Jan,0.121901375,0.342976751,0.913991394,0,0,8.047773279,16.9368846,ELOVL6
60,Butanoate metabolism,28-Jan,0.12612194,0.347069117,0.899209358,0,0,7.749317739,16.04500936,HMGCS1
61,Relaxin signaling pathway,2/129,0.127537446,0.347069117,0.894362283,0,0,3.313285307,6.823198393,NRAS;MMP2
62,Circadian rhythm,31-Jan,0.138663557,0.371260492,0.858037663,0,0,6.973333333,13.77724766,CLOCK
63,Fluid shear stress and atherosclerosis,2/139,0.14380531,0.37891558,0.842225076,0,0,3.069886628,5.953415496,MEF2C;MMP2
64,Apoptosis,2/142,0.148768814,0.385869112,0.827488099,0,0,3.003647416,5.723034929,NRAS;ITPR3
65,Breast cancer,2/147,0.157117466,0.39843628,0.803775533,0,0,2.899339692,5.365986453,NRAS;CCND1
66,Gastric cancer,2/149,0.160481875,0.39843628,0.794574011,0,0,2.859603416,5.231856843,NRAS;CCND1
67,Adrenergic signaling in cardiomyocytes,2/150,0.162169139,0.39843628,0.790031789,0,0,2.84013801,5.166538848,AGTR2;ATP2B1
68,"Alanine, aspartate and glutamate metabolism",1/37,0.163214862,0.39843628,0.787240298,0,0,5.809356725,10.53054992,CPS1
69,Hepatitis C,2/157,0.174067997,0.415544296,0.759281068,0,0,2.710912835,4.739514036,NRAS;CCND1
70,Nicotine addiction,1/40,0.175229523,0.415544296,0.756392722,0,0,5.361673414,9.338204649,GRIA2
71,Hippo signaling pathway,2/163,0.184377422,0.431079606,0.734292262,0,0,2.60909211,4.411375755,CCND1;BMP5
72,Wnt signaling pathway,2/166,0.189565704,0.437054262,0.722240232,0,0,2.56097561,4.258952614,CCND1;LGR5
73,Hepatocellular carcinoma,2/168,0.193035853,0.437153664,0.714362021,0,0,2.529864137,4.161321252,NRAS;CCND1
74,Glycosphingolipid biosynthesis,1/45,0.19487573,0.437153664,0.710242245,0,0,4.751196172,7.77007394,B3GALT2
75,"Valine, leucine and isoleucine degradation",1/48,0.206440413,0.456921447,0.685205281,0,0,4.447256439,7.016629791,HMGCS1
76,Cocaine addiction,1/49,0.210258657,0.45830591,0.677246114,0,0,4.354385965,6.790302654,GRIA2
77,Human papillomavirus infection,3/331,0.212587681,0.45830591,0.672461905,0,0,1.925255704,2.981067393,NRAS;RELN;CCND1
78,NOD-like receptor signaling pathway,2/181,0.215777549,0.459218886,0.665993744,0,0,2.34458576,3.595439303,TRIP6;ITPR3
79,Endocrine and other factor-regulated calcium reabsorption,1/53,0.225350677,0.473521676,0.647141133,0,0,4.018623482,5.988140905,ATP2B1
80,Hedgehog signaling pathway,1/56,0.236482063,0.479527991,0.626201794,0,0,3.798851675,5.477499329,CCND1
81,Legionellosis,1/57,0.240157235,0.479527991,0.619504326,0,0,3.730827068,5.321880898,EEF1A2
82,PI3K-Akt signaling pathway,3/354,0.241640045,0.479527991,0.616831091,0,0,1.796985571,2.552269525,NRAS;RELN;CCND1
83,VEGF signaling pathway,1/59,0.247455139,0.479527991,0.606503523,0,0,3.601814882,5.030028025,NRAS
84,Viral myocarditis,1/60,0.251078036,0.479527991,0.600191277,0,0,3.54058876,4.893063524,CCND1
85,Mineral absorption,1/60,0.251078036,0.479527991,0.600191277,0,0,3.54058876,4.893063524,ATP2B1
86,Focal adhesion,2/201,0.251184079,0.479527991,0.600007891,0,0,2.106810649,2.910704754,RELN;CCND1
87,Pathways in cancer,4/531,0.251318887,0.479527991,0.599774873,0,0,1.598630476,2.207760933,NRAS;CCND1;MECOM;MMP2
88,Rap1 signaling pathway,2/210,0.267192718,0.489622434,0.573175383,0,0,2.014729951,2.659010554,NRAS;RAPGEF5
89,Human immunodeficiency virus 1 infection,2/212,0.270751505,0.489622434,0.567429121,0,0,1.995339412,2.607018363,NRAS;ITPR3
90,cAMP signaling pathway,2/216,0.277868045,0.489622434,0.556161394,0,0,1.957645655,2.506978518,GRIA2;ATP2B1
91,Fc epsilon RI signaling pathway,1/68,0.279446625,0.489622434,0.553701131,0,0,3.11657502,3.973458529,NRAS
92,Mitophagy,1/68,0.279446625,0.489622434,0.553701131,0,0,3.11657502,3.973458529,NRAS
93,Amphetamine addiction,1/69,0.282917076,0.489622434,0.54834084,0,0,3.070588235,3.876929138,GRIA2
94,Renal cell carcinoma,1/69,0.282917076,0.489622434,0.54834084,0,0,3.070588235,3.876929138,NRAS
95,Renin secretion,1/69,0.282917076,0.489622434,0.54834084,0,0,3.070588235,3.876929138,ITPR3
96,Central carbon metabolism in cancer,1/70,0.286370984,0.489622434,0.543070988,0,0,3.025934401,3.7838316,NRAS
97,RIG-I-like receptor signaling pathway,1/70,0.286370984,0.489622434,0.543070988,0,0,3.025934401,3.7838316,SIKE1
98,Adherens junction,1/71,0.289808429,0.489622434,0.537888987,0,0,2.982556391,3.694000965,YES1
99,p53 signaling pathway,1/73,0.296634239,0.489622434,0.527778722,0,0,2.899415205,3.523530039,CCND1
100,PPAR signaling pathway,1/74,0.300022757,0.489622434,0.522845802,0,0,2.859552992,3.442607126,HMGCS1
101,Thyroid hormone synthesis,1/75,0.30339512,0.489622434,0.517991408,0,0,2.820768137,3.364384584,ITPR3
102,Ras signaling pathway,2/232,0.306275639,0.489622434,0.513887545,0,0,1.819981499,2.153529146,NRAS;RAPGEF5
103,Gastric acid secretion,1/76,0.306751405,0.489622434,0.51321344,0,0,2.783017544,3.288740858,ITPR3
104,Pancreatic cancer,1/76,0.306751405,0.489622434,0.51321344,0,0,2.783017544,3.288740858,CCND1
105,Leishmaniasis,1/77,0.310091686,0.490240189,0.508509878,0,0,2.746260388,3.215561314,EEF1A2
106,RNA degradation,1/79,0.31672454,0.494352193,0.499318286,0,0,2.675573549,3.076168025,DDX6
107,Chemical carcinogenesis,2/239,0.318648702,0.494352193,0.496687846,0,0,1.765598348,2.019254852,NRAS;CCND1
108,B cell receptor signaling pathway,1/81,0.323294283,0.496915287,0.490401975,0,0,2.608421053,2.945408908,NRAS
109,Shigellosis,2/246,0.330972092,0.501654491,0.480208626,0,0,1.714335542,1.895577192,UBE2D3;ITPR3
110,ErbB signaling pathway,1/85,0.336246807,0.501654491,0.473341831,0,0,2.483709273,2.707019184,NRAS
111,Taste transduction,1/86,0.339446416,0.501654491,0.469228773,0,0,2.454365325,2.651792453,ITPR3
112,Insulin secretion,1/86,0.339446416,0.501654491,0.469228773,0,0,2.454365325,2.651792453,ITPR3
113,Endocytosis,2/252,0.341487696,0.501654491,0.46662494,0,0,1.672680851,1.797201287,IQSEC1;ARAP2
114,ECM-receptor interaction,1/88,0.345799913,0.503533207,0.46117512,0,0,2.397701149,2.546106758,RELN
115,PD-L1 expression and PD-1 checkpoint pathway in cancer,1/89,0.348953946,0.503707435,0.457231886,0,0,2.370334928,2.495524938,NRAS
116,Morphine addiction,1/91,0.355216937,0.508327686,0.449506335,0,0,2.317426901,2.398598453,KCNJ3
117,Small cell lung cancer,1/92,0.358326037,0.508394206,0.445721634,0,0,2.291844997,2.352147999,CCND1
118,TGF-beta signaling pathway,1/94,0.364499797,0.509960353,0.438302709,0,0,2.242331636,2.263026751,BMP5
119,Fc gamma R-mediated phagocytosis,1/97,0.373650385,0.509960353,0.427534566,0,0,2.171929825,2.138123125,MARCKS
120,Phosphatidylinositol signaling system,1/97,0.373650385,0.509960353,0.427534566,0,0,2.171929825,2.138123125,ITPR3
121,Choline metabolism in cancer,1/98,0.37667151,0.509960353,0.424037227,0,0,2.149430277,2.098664596,NRAS
122,Inflammatory mediator regulation of TRP channels,1/98,0.37667151,0.509960353,0.424037227,0,0,2.149430277,2.098664596,ITPR3
123,Prion disease,2/273,0.377862189,0.509960353,0.422666564,0,0,1.541414776,1.500144519,EGR1;ITPR3
124,Melanogenesis,1/101,0.385648632,0.515642785,0.413808205,0,0,2.084631579,1.986296596,NRAS
125,Longevity regulating pathway,1/102,0.388612481,0.515642785,0.410483256,0,0,2.063887441,1.950729911,NRAS
126,Protein digestion and absorption,1/103,0.391562179,0.515642785,0.407199263,0,0,2.043550052,1.916054913,COL24A1
127,T cell receptor signaling pathway,1/104,0.394497794,0.515642785,0.403955421,0,0,2.023607563,1.882241842,NRAS
128,Pathways of neurodegeneration,3/475,0.399703932,0.518366037,0.39826158,0,0,1.328048114,1.217861524,GRIA2;NRAS;ITPR3
129,Glucagon signaling pathway,1/107,0.4032208,0.518873277,0.394457073,0,0,1.966037736,1.785695015,ITPR3
130,Cytokine-cytokine receptor interaction,2/295,0.41507272,0.530015934,0.381875809,0,0,1.424079588,1.252195383,GDF11;BMP5
131,Leukocyte transendothelial migration,1/114,0.423093827,0.536134163,0.373563311,0,0,1.843595715,1.585789707,MMP2
132,Sphingolipid signaling pathway,1/119,0.436886495,0.544586058,0.35963138,0,0,1.765031222,1.461590327,NRAS
133,Neurotrophin signaling pathway,1/119,0.436886495,0.544586058,0.35963138,0,0,1.765031222,1.461590327,NRAS
134,AMPK signaling pathway,1/120,0.439605613,0.544586058,0.356936771,0,0,1.750110571,1.438376128,CCND1
135,Cell cycle,1/124,0.450352761,0.549695282,0.34644717,0,0,1.692854086,1.350430485,CCND1
136,Platelet activation,1/124,0.450352761,0.549695282,0.34644717,0,0,1.692854086,1.350430485,ITPR3
137,Oocyte meiosis,1/129,0.463500269,0.561613465,0.333950009,0,0,1.626315789,1.250552783,ITPR3
138,Natural killer cell mediated cytotoxicity,1/131,0.468671699,0.563764508,0.329131271,0,0,1.601133603,1.213423516,NRAS
139,Vascular smooth muscle contraction,1/133,0.473793795,0.565825683,0.324410632,0,0,1.576714514,1.17777907,ITPR3
140,Autophagy,1/137,0.483891842,0.566405034,0.3152517,0,0,1.53003096,1.110640087,NRAS
141,Insulin signaling pathway,1/137,0.483891842,0.566405034,0.3152517,0,0,1.53003096,1.110640087,NRAS
142,Measles,1/139,0.488868711,0.566405034,0.310807758,0,0,1.507704043,1.07900545,CCND1
143,Neuroactive ligand-receptor interaction,2/341,0.489096671,0.566405034,0.310605293,0,0,1.22795456,0.878227106,GRIA2;AGTR2
144,Ubiquitin mediated proteolysis,1/140,0.491339306,0.566405034,0.308618492,0,0,1.496781522,1.063643391,UBE2D3
145,Signaling pathways regulating pluripotency of stem cells,1/143,0.498680407,0.570903087,0.302177695,0,0,1.46493699,1.019288296,NRAS
146,Phospholipase D signaling pathway,1/148,0.510683284,0.580639898,0.291848358,0,0,1.414751164,0.950720815,NRAS
147,Spliceosome,1/150,0.515404409,0.582021306,0.287851871,0,0,1.395619922,0.925021666,BCAS2
148,Amyotrophic lateral sclerosis,2/364,0.523897719,0.584578293,0.280753492,0,0,1.148583519,0.74251193,GRIA2;ITPR3
149,mTOR signaling pathway,1/154,0.524711841,0.584578293,0.280079135,0,0,1.358857929,0.876335688,NRAS
150,Alzheimer disease,2/369,0.531253773,0.586873031,0.274697972,0,0,1.132645371,0.716415703,NRAS;ITPR3
151,Ribosome,1/158,0.533842335,0.586873031,0.272586989,0,0,1.323969159,0.830995513,MRPL1
152,JAK-STAT signaling pathway,1/162,0.54279922,0.592793885,0.265360785,0,0,1.290813992,0.788707728,CCND1
153,Tight junction,1/169,0.558065814,0.60548317,0.253314581,0,0,1.236591479,0.721277072,CCND1
154,Protein processing in endoplasmic reticulum,1/171,0.562334276,0.606152531,0.250005444,0,0,1.221919505,0.703408726,UBE2D3
155,Alcoholism,1/186,0.593073491,0.631091023,0.226891487,0,0,1.121991465,0.586169806,NRAS
156,RNA transport,1/186,0.593073491,0.631091023,0.226891487,0,0,1.121991465,0.586169806,EEF1A2
157,Neutrophil extracellular trap formation,1/189,0.598959906,0.633295188,0.222602248,0,0,1.103919373,0.565825595,CLCN3
158,Chemokine signaling pathway,1/192,0.604762045,0.635382908,0.218415473,0,0,1.08641499,0.546380057,NRAS
159,Epstein-Barr virus infection,1/202,0.623509052,0.64878469,0.205157237,0,0,1.031840796,0.487433332,CCND1
160,Diabetic cardiomyopathy,1/203,0.625334641,0.64878469,0.203887512,0,0,1.026680563,0.481994026,MMP2
161,Lipid and atherosclerosis,1/215,0.646570148,0.666649966,0.189384351,0,0,0.968519429,0.422345737,NRAS
162,Regulation of actin cytoskeleton,1/218,0.651690159,0.667781274,0.185958837,0,0,0.954984235,0.408910924,NRAS
163,Thermogenesis,1/232,0.67462957,0.687046065,0.170934627,0,0,0.896468444,0.352842381,NRAS
164,Salmonella infection,1/249,0.700482661,0.704728011,0.15460261,0,0,0.834295416,0.296997209,AHNAK
165,Parkinson disease,1/249,0.700482661,0.704728011,0.15460261,0,0,0.834295416,0.296997209,ITPR3
166,Huntington disease,1/306,0.773203376,0.773203376,0.111706258,0,0,0.676410699,0.173981737,GRIA2